Amid the Federal Trade Commission's (FTC's) campaign to bolster scrutiny around large biopharma M&A deals, the agency is now taking a closer look at patent gamesmanship.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,